Prediction of Adalimumab Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive Spondyloarthritis: Pilot Study

The main objective of this trial is to search for biomarkers associated with the success of adalimumab treatment in order to generate an algorithm to predict the response to this treatment at 6 months in spondyloarthritis and to define its metrological properties on this cohort.
The algorithm will allow to better target patients who will have an important benefit/risk ratio for adalimumab treatment.

Start Date14 Jun 2018

Sponsor / Collaborator

Centre Hospitalier Universitaire de Grenoble

[+1]

100 Clinical Results associated with Sinnovial SAS

0 Patents (Medical) associated with Sinnovial SAS

Literatures (Medical) associated with Sinnovial SAS

01 Sep 2019·Rheumatology

Calprotectin discriminates septic arthritis from pseudogout and rheumatoid arthritis

Article

Author: Romand, Xavier ; Toussaint, Bertrand ; Baillet, Athan ; Epaulard, Olivier ; Trocmé, Candice ; Nguyen, Chuong M.V. ; Gaudin, Philippe ; Courtier, Anais

AbstractObjectiveWe aimed to determine whether calprotectin and α-defensins could discriminate septic from other inflammatory arthritides.MethodsSynovial fluids with a predominance of neutrophils from patients with septic arthritis, pseudogout and RA were prospectively collected. Neutrophil-related proteins calprotectin and human neutrophil α-defensins levels were assessed in synovial fluids. Demographic parameters and biomarkers with P-value ⩽0.05 for differentiating septic from non-septic arthritis were included in a multivariable model. Multivariable logistic regression with stepwise selection was performed to build the final combined model.ResultsA total of 74 patients were included: septic arthritis (n = 26), pseudogout (n = 28) and RA (n = 20). Patients with septic arthritis were more likely to be male and young, and to display higher synovial neutrophil count. Calprotectin was significantly increased in patients with septic arthritis. The multivariable model included calprotectin, synovial fluid neutrophil count and gender. Calprotectin was the only biomarker that discriminated septic arthritis from non-septic inflammatory arthritides, with 76% sensitivity, 94% specificity and a positive likelihood ratio = 12.2 at the threshold for calprotectin of 150 mg/l.ConclusionSynovial fluid calprotectin is a relevant biomarker to discriminate septic arthritis from other inflammatory arthritides. This biomarker should be tested in an independent cohort.

100 Deals associated with Sinnovial SAS

100 Translational Medicine associated with Sinnovial SAS

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 12 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sinnovial SAS

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 12 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing